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Abstract An orally-active antagonist of neuropeptide Y (NPY) 
YI receptors, SR 120819A, has been characterized. This com- 
pound displays highly selective and competitive affinity for rat, 
guinea-pig and human (K i = 15 nM) NPY Y1 receptors. In vitro, 
SR 120819A blocks the inhibitory effect of NPY on adenylyl 
cyclase activity in human SK-N-MC cells and that of the selective 
Y1 agonist, [Leu31,Pro34]NpY, on rabbit vas deferens contraction 
(pA 2 = 7.20 + 0.07). In vivo, by intravenous route, this compound 
acts as an antagonist in anesthetized guinea-pigs and, notably, 
after oral administration, SR 120819A counteracts the pressor 
response of [Leu31,Pro34]NpY (5/xg/kg i.v.) with a long duration 
of action (>4 h at 5 mg/kg p.o.). Thus, SR 120819A is the first 
orally-effective NPY Y~ receptor antagonist yet described. It 
could be a useful tool for exploring the role of NPY and the 
therapeutic relevance of an antagonist at NPY Y~ receptors. 
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we recently reported the design of the first potent, selective and 
orally-effective NPY Y1 receptor antagonists yet described [10]. 
An antagonist of NPY Y~ receptors active in vitro and in vivo 
by intravenous route has also been recently claimed [11]. Based 
on the known interactions of NPY with Y1 receptors [12-14], 
we designed SR 120819A (1 -[2-[2-(2-naphtylsulfamoyl)-3-phen- 
ylpropionamido]-3-[4-[N-[4-(dimethylaminomethyl)-cis-cyclohex- 
ylmethyl]amidino]phenyl]propionyl]pyrrolidine, (R,R) stereo- 
isomer) (Fig. 1), a member of an original chemical series of 
selective and orally-active NPY Y~ antagonists. In the present 
study, we characterize the biochemical and pharmacological 
profile of this compound. Since marked species differences have 
been reported for several peptide ligand receptors [15] and in 
the amino acid sequence of cloned Yi receptors [16,17], special 
attention was paid to the evaluation of SR 120819A at human 
NPY Y~ receptors in binding and functional studies, using the 
human euroblastoma cell line SK-N-MC which only expresses 
Y~ receptors. 
I. Introduction 
Neuropeptide Y (NPY) is a 36 amino-acid regulatory peptide 
abundantly found in the central and peripheral nervous ystem 
of mammals [1]. Related to its widespread istribution, NPY 
exerts a variety of biological effects, especially on cardiovascu- 
lar regulation, food intake, metabolism, behavioral and endo- 
crine functions via three proposed receptor subtypes, Y~, Y2 
and Y3 [2]. In particular, through post synaptic Y~ receptors, 
NPY and the related peptide, PYY, have potent vasoconstric- 
tor effects on crucial territories uch as coronary and cerebral 
vessels [3-5]. Among various central effects, the Y~ receptor 
subtype also seems to be involved in the powerful stimulation 
of food intake by NPY [6]. 
Several lines of evidence have underlined the potential role 
of NPY in varying pathological states uch as in some forms 
of hypertension, vasospasm, yocardial infarction, obesity and 
boulimia [7,8]. Accordingly, the search for selective, orally- 
active NPY antagonists appears essential both for further in- 
vestigating the role of NPY and for designing a new class of 
potential therapeutical agents. Until now, however, no peptide 
or non-peptide antagonist with reasonable affinity or selectivity 
at NPY receptors was available (for review see [9]). In this field, 
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2. Materials and methods 
2.1. Materials 
Chemicals. SR 120819A (1-[2-[2-(2-naphtylsulfamoyl)-3-phenyl- 
propionamido]-3-[4-[N-[4-(dimethylaminomethyl)-cis-cyclohexylmeth- 
yl]amidino]phenyl]propionyl]-pyrrolidine, (R,R) stereoisomer) (Fig. 1) 
was synthesized in Sanofi Recherche (Toulouse, France). This com- 
pound was dissolved either in distilled water at 10 -2 M or in the appro- 
priate test solvent. NPY, [Leu31,Pro34]NpY and bacitracin were from 
Sigma Chemical Co. (L'isle d'Abeau, France). Bovine serum albumin 
was obtained from Biosepra (Paris, France). Tissue culture reagents 
were from Boehringer-Mannheim (Meylan, France). EDTA, HEPES 
were purchased from Merck-Clevenot (Nogent sur Marne, France). All 
other chemicals were from Prolabo (Paris, France). The radioligands, 
125I-NPY and L25I-PYY (2,000 Ci/mmol), were from Amersham and 
New England Nuclear (Les Ulis, France), respectively, and cAMP 
assay kits were obtained from Amersham. 
Biological materials. Male Wistar ats (250-350 g) were from Iffa- 
Credo (Lyon, France). Male New Zealand rabbits (2.5 3 kg) from 
Gendre (Lusignan, France) were used for in vitro isolated preparations, 
and Hartley guinea-pigs (300~J,00 g)were from Charles River (France). 
SK-N-MC cells, isolated from a human metastatic neuroblastoma, 
were purchased from the American Type Culture Collection (ATCC, 
HTB 10) (Rockville, MD). Frozen human cortex was obtained from the 
International Institute for the Advancement of Medicine, the Key Stone 
Skin Bank (Exton, USA). 
2.2. Cell culture 
SK-N-MC cells, plated in 175 cm 2 culture flasks, were grown in 
minimal essential medium (MEM) with Earle's alts upplemented with 
10% fetal calf serum, 1% nonessential amino acids, 1 mM sodium 
pyruvate, 1% vitamins, 4mM glutamine, penicillin-G (100 IU/ml) and 
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streptomycin (100/ag/ml) in a 95% air, 5% CO2 humidified atmosphere 
at 37°C. Culture medium was removed every other day and SK-N-MC 
cells were subcultured by treatment with 0.05% trypsin, 0.02% EDTA. 
2.3. Membrane preparations 
Rat, guinea-pig and human cortex plasma membranes (P2 fraction) 
were obtained by the method of Unden [18] and stored as aliquots in 
liquid nitrogen until required. SK-N-MC membranes from confluent 
cells were prepared as previously described [19]. Protein concentration 
was determined by the method of Bradford using bovine serum albumin 
as a standard [20]. 
2.4. Binding assays 
In binding experiments, membranes (0.1 mg/ml) from rat, guinea-pig 
or human cortex, or from SK-N-MC cells were incubated for 60 min 
at 30°C in a Krebs-Ringer buffer (pH 7.4) containing 20 mM HEPES, 
1% bovine serum albumin, 0.25 mg/ml bacitracin and 0.1 nM *2SI-NPY 
or ~2sI-PYY. The reaction was stopped by rapid filtration through 
Whatman GF/C filters, washed with 3 × 4 ml of ice-cold buffer and the 
radioactivity, bound to the filters, was measured by scintillation count- 
ing. Non-specific binding was determined in the presence of 0.3/.tM 
porcine NPY. All experiments were carried out in duplicate. Data from 
binding experiments were analyzed using a non-linear regression pro- 
gram [21] and inhibition constants (K~) value calculated according to 
Cheng and Prusoff equation [22]. 
For selectivity, binding assays were carried out using standard proto- 
cols [23]. 
2.5. Adenylyl cyclase assays 
SK-N-MC cells, cultured in 24-well plates, were incubated for 10 min 
in a 2.5 mM HEPES/Tris medium (pH 7.5) containing 140 mM NaCI, 
5 mM KCI, 1.8 mM CaCI2, 0.2% bovine serum albumin, 4.5 g/l glucose 
and 1 mM isobuthyl-methyl-xanthine. Different concentrations of SR 
120819A (or vehicle) were added 1 min prior to the addition of 10 nM 
NPY. 1 min later, 0.5/IM forskolin was added and the incubation was 
performed 20 min. The reaction was stopped by aspiration of the 
medium and rapid addition of 1 ml methanol. After extraction, cAMP 
content was measured using cAMP assay kits. 
2.6. Isolated rabbit vas deferens preparations 
The prostatic segments of male New Zealand rabbits' vas deferentia 
were studied as previously described [24]. Electrical field stimulation 
consisted of rectangular bipolar pulses of 1 ms duration and of 0.1 Hz 
frequency, applied at a submaximal voltage. The antagonist effect of 
SR 120819A on [Leu3~,Pro34]NPY-induced twitch contraction inhibi- 
tion was expressed by a pA 2 value calculated according to Van Ros- 
sum's method [25]. 
2.7. Arterial blood pressure in anesthetized guinea pigs in vivo 
Guinea-pigs were anesthetized with sodium pentobarbital (30 mg/kg 
i.p.) and assays performed as in [26]. Diastolic blood pressure was 
measured using a Statham P10EZ pressure transducer coupled to a RS 
3400 polygraph (Gould). SR 120819A was injected intravenously (0.1 1 
mg/kg) into anesthetized animals, or orally (1 to 10 mg/kg) 50 min prior 
to anesthesia, and tested on 5 pg/kg i.v. [Leu3~,Pro34]NPY-induced 
hypertension which was injected at different times. All values are given 
as means + S.E.M. and statistical nalysis of data was performed with 
Anovarep followed by a Dunnet's t-test for multiple comparisons. The 
level of significance was taken as *P < 0.05. 
3. Results 
3.1. Interaction of SR 120819A with rat, guinea-pig and human 
NP Y }'1 receptors and selectivity profile 
SR 120819A (Fig. 1), inhibited in a concentration-dependent 
manner ~25I-NPY and 125I-PYY specific binding to NPY Y~ 
receptors in rat and guinea-pig cortex, and in the human neu- 
roblastoma SK-N-MC cell line. Hill coefficient values were 
close to unity compatible with a single-site competitive model. 
It is important o note that, under similar experimental condi- 
tions, K~ (inhibition constant) values were in the 10 nanomolar 
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Fig. 1. Chemical structure of SR 120819A. 
range and were similar in the three species, including man 
(Table 1). 
Saturation binding experiments were performed on human 
SK-N-MC preparation, in the presence or absence of SR 
120819A (15 and 30 nM). Scatchard analysis of data demon- 
strated that SR 120819A interacted with human Y~ receptors 
in a fully competitive manner since in the presence of this 
molecule the apparent dissociation constant (Kd) was signifi- 
cantly changed, whereas the maximal binding capacity (Bmax) 
was not modified (Fig. 2A). The K~ value calculated from 
Scatchard plots (K~ -- 15 nM) was in good agreement with that 
obtained according to the Cheng and Prusoff equation [22] 
from competition experiments (Ki = 17 + 6 nM). 
The selectivity of SR 120819A for NPY Yj receptors was 
evaluated by measuring the ability of this compound to interact 
with NPY Y2 or Y3 receptors. As shown in Table 1, SR 
120819A was highly selective, since at 10 pM it did not bind to 
human cortex Y2 receptors. In addition, it did not inhibit the 
functional contractile response of NPY in the Y3 rat colon 
model [27] in concentrations of up to 1/ IM (5 + 2% inhibition 
at 1 /~M). Moreover, in thirty classical binding assays, SR 
120819A, 1 ~tM, did not interact with receptors of non-peptide 
or peptide ligands (data not shown). 
3.2. Effect of  SR 120819A on adenylyl cyclase activity in 
SK-NM-C cells 
The signalling mechanisms, linked to the NPY YI receptor 
subtype, involved Ca 2÷ mobilization and adenylyl cyclase inhi- 
bition, and both mechanisms have been observed in SK-N-MC 
Table 1 
Affinity of SR 120819A for NPY Y~ and Y2 receptors 
Y~ Y2 
K, (nM) Inhibition (%) 
at 10 ,uM 
Tissues Rat Guinea-pig Human Human 
cortex cortex SK-N-MC cortex 
cells 
Ligands 
125I-NPY 15 + 6 22 + 6 21 + 8 0 
125I-PYY 11 + 3 20 _+ 5 17 _+ 6 0 
Binding assays were performed as described in section 2.4 using 100 pM 
~25I-NPY or ~:5I-PYY, 20/lg protein membranes and increasing concen- 
trations of SR 120819A (10 -~° to 10 -5 M). Inhibition constants (K~) were 
determined from competition experiments calculated according to 
Cheng and Prusoff's equation [22]. Values are given as the mean + S.D. 
of 3 to 6 independent determinations performed in duplicate. 
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Fig. 2. Binding (A) and adenylyl cyclase activity (B) of SR 120819A at human NPY Y I receptors in SK-N-MC cells. (A) Scatchard plots of 125I-PYY 
binding to human SK-N-MC membranes without (e) or with 15 ([]) and 30 (v) nM SR 120819A. The radioligand (100 pM) was incubated alone 
or in the presence of increasing concentrations of PYY with membranes (20/~g protein) for 1 h at 30°C. Each point is the mean calculated from 
a typical experiment performed in duplicate. (B) SR 120819A antagonism on 10 nM NPY-induced cAMP inhibition in SK-NM-C cells. Histograms 
represent the effect of 0.5/tM forskolin (FK) alone or in the presence of either 1 ~tM SR 120819A or 10 nM NPY. The results are expressed as a 
percent of maximal 0.5/IM forskolin (FK) effect. Each point is the mean + S.E.M. of 3 independent experiments performed in triplicate. 
cells [28]. In order to determine the agonist or antagonist prop- 
erties of SR 120819A, we examined the activity of this com- 
pound on NPY-induced inhibition of 0.5/tM forskolin-evoked 
cAMP accumulation i SK-N-MC cells, in vitro. As shown in 
Fig. 2B, SR 120819A by itself did not affect the cAMP level 
significantly at 1 ~tM, but dose-dependently antagonized NPY 
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Fig. 3. Effect of SR 120819A on the electrically-stimulated rabbit vas 
deferens. Cumulative concentration-response curves for 
[Leu3~,Pro34]NPY on the amplitude of twitch contractions elicited by 
electrical field stimulation were established in the absence (e) or in the 
presence of 0.1 (&), 0.3 (*) and 1 (v)/aM of SR 120819A. Results are 
expressed as percentage ofthe twitch control responses measured after 
45 min incubation with or without SR 120819A and are the 
mean + S.E.M. of 5 to 6 experiments. 
inhibition of cAMP accumulation with an ICs0 value (with 95% 
confidence interval) of 92 nM (66-140) (n = 3). 
3.3. Effect of SR 120819A on the eleetrically-stimulated rabbit 
vas deferens 
In vitro, in the Y~ isolated rabbit vas deferens model, the 
selective Yl receptor agonist [Leu31,Pro34]NpY, induced rapid, 
concentration-dependent inhibition of the twitch contractions 
with a pD 2 value of 8.32 + 0.03 (n = 6) consistent with what has 
been already published [24]. SR 120819A (0.3 to 1 pM) pro- 
duced a parallel rightward shift in the [Leu31,Pro34]NpY con- 
centration-response curve without significantly affecting the 
maximal contractile response (Fig. 3). Schild analysis of these 
data yielded a pA2 value of 7.20 + 0.07 with a slope about one, 
indicating competitive antagonism against [Leu31,Pro34]NPY. 
In addition, SR 120819A exhibited no NPY agonist activity in 
modifying the electrically-induced twitch contraction in con- 
centrations of up to 10 pM, when tested alone. 
3.4. Effect of SR 120819A in anesthetized guinea-pigs in vivo 
In anesthetized guinea-pigs, 5 pg/kg of [Leu31,Pro34]NpY i.v. 
induced a rise in diastolic blood pressure of approximately 20 
mmHg. No tachyphylaxis occurred in this preparation after 
repeated injections eparated by 30 min (Fig. 4). Bolus intrave- 
nous injection of SR 120819A (0.1 to 1 mg/kg) caused dose- 
dependent inhibition of the pressor response to exogenous 
[Leu31,Pro34]NpY (5/.tg/kg i.v.). The inhibitory effect of SR 
120819A lasted significantly for 3 h at the highest dose (1 
mg/kg) (Fig. 4A). When administered orally, SR 120819A (1 to 
10 mg/kg) also inhibited the YI agonist hypertensive r sponse 
in a concentration-dependent manner. The inhibitory effect 
was significant at the two highest doses of 5 and 10 mg/kg and 
was maintained for at least 4 h, demonstrating a long lasting 
oral effect of SR 120819A (Fig. 4B). It is important to underline 
that no significant intrinsic agonistic effect was observed with 
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Fig. 4. Time-course of the inhibitory effect of SR 120819A intravenously (A) and per os (B) on [Leu 3],PrO34]NPY (5/zg/kg i.v.)-induced hypertension 
in anesthetized guinea-pigs. Data are expressed as a change in diastolic blood pressure, observed after each [Leu3~,Pro34]NPY injection and represent 
the mean + S.E.M. of 5 to 11 determinations per group. Statistical analysis was performed using Anovarep followed by Dunnett's test and the level 
of significance was taken as *P < 0.05. 
SR 120819A after intravenous or oral administration (not 
shown). 
4. Discussion 
The present study indicates that SR 120819A is a potent and 
selective ligand of NPY Y] receptors and displays both in vitro 
and in vivo antagonistic properties against NPY or 
[Leu3~,Pro34]NpY response. Moreover, SR 120819A is the first 
orally-active NPY Y~ receptor antagonist, yet described. 
So far, three NPY receptor subtypes have been identified and 
mediate the diverse biological effects described for this peptide 
[2]. The NPY Y] receptor subtype clearly supports the powerful 
pressor and vasoconstrictor action of NPY and seems also to 
be involved in several of its behavioural effects [3-6]. Further- 
more, because NPY might be intimately implicated in several 
diseases (hypertension, heart failure, vasospasm [7-9]), the de- 
velopment of potent and specific NPY antagonists with, in 
addition, good oral bioavailability, may offer novel therapeuti- 
cal approaches. Since in this field no compounds with such a 
profile are yet available, SR 120819A represents an important 
step forward in this research. 
This compound isplays high, selective affinity for NPY Yt 
receptors in vitro: in our binding studies, SR 120819A had 
similar affinity for NPY Y1 receptors in different animal species 
(rat, guinea-pig) and, in particular, in the human neuroblas- 
toma cell line, SK-N-MC (Kt = 15 riM). In this latter model, it 
has been shown that SR 120819A interacts in a fully competi- 
tive manner at NPY Yj receptors. 
It is also important to underline the highly selective profile 
of this compound for Yl receptors versus other NPY receptor 
subtypes (Y2 and Y3) and various receptors in general as evi- 
denced in several binding tests in vitro. 
In addition, several functional studies in vitro and in vivo 
have been performed to address the antagonist or agonist prop- 
erties of SR 120819A. The human neuroblastoma cell line, 
SK-N-MC, expressing selectively the functional Y~ receptor 
subtype has provided an essential model for investigating both 
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the interaction and the subsequent activity of SR 120819A at 
NPY Y1 receptors from human origin. Moreover, the two sig- 
nalling mechanisms, i.e. Ca 2+ mobilization and adenylyl cyclase 
inhibition, linked to NPY Y1 receptor activation, have been 
demonstrated in SK-N-MC cells [28]. Studied in this model, SR 
120819A dose-dependently inhibited the second messenger re- 
sponse elicited by NPY on adenylyl cyclase activity. Further- 
more, we observed a good correlation between the binding 
affinity of SR 120819A to SK-N-MC Yl receptors and the 
antagonism on the physiological response of NPY on cAMP 
accumulation. Other results, in the electrically-stimulated rab- 
bit vas deferens, previously characterized as a Y~ model [24], 
confirmed the full competitive antagonist profile of SR 
120819A in vitro (pA 2 = 7.20 + 0.07). 
As NPY is one of the most potent contractile agents de- 
scribed so far and could be involved in the control of blood 
pressure in normal or even pathological situations via Yj recep- 
tors [3-5], the effect of SR 120819A on arterial blood pressure 
was investigated in anesthetized guinea-pigs. In this model, SR 
120819A has shown considerable ffect in antagonizing the 
hypertensive effect of [Leu3~,Pro34]NpY both by intravenous 
and oral routes. A remarkably long-lasting oral effect (>4 h at 
5 mg/kg) together with the absence of agonist activity were 
observed. 
Taken together, all these observations allow us to conclude 
that SR 120819A has a selective, orally-active Y] receptor an- 
tagonist profile. Therefore, this compound may be a promising 
tool for further studying the role of NPY, its receptor function, 
and also for exploring the therapeutic relevance of a NPY Yi 
receptor antagonist in various disorders. 
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